Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Genedrive shares jump on NICE test recommendation
(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test. The AIM-traded firm said that in draft guidance, NICE recommended the point-of-care (POC) genetic test before administering clopidogrel in the management of ischemic stroke (IS) and transient ischaemic attack (TIA) patients.
Clopidogrel, an antiplatelet drug crucial in reducing the risk of blood clots following IS or TIA, relies on metabolism by an enzyme encoded by the CYP2C19 gene.
However, variations in that gene could hinder the enzyme's function, leading to suboptimal response to clopidogrel in certain individuals.
The company described the Genedrive CYP2C19-ID test as a swift and non-invasive solution, using a single cheek swab sample to identify six key genetic variants of the CYP2C19 gene.
It said the Genedrive System then promptly interpreted that information for clinicians, enabling tailored treatment plans.
With more than 77 million global cases of ischaemic stroke reported by the World Stroke Organization, and around 100,000 strokes occurring annually in the UK according to the Stroke Association, there was a strong need for effective antiplatelet treatment.
Suboptimal response affected 20% to 30% of the general UK stroke population, rising to 50% to 60% in specific ethnic groups.
NICE's draft guidance, issued in May last year, emphasised the importance of CYP2C19 genetic testing before antiplatelet treatment for IS or TIA.
A public consultation on the draft guidance was ongoing until 26 April, with final recommendations anticipated on 10 July.
Highlighting the superiority of the Genedrive platform, the company said NICE recommended it as the preferred POC system for CYP2C19 genotyping in the NHS.
That decision was reportedly based on various distinguishing features, including broader coverage of genetic variants, eliminating the need for cold-chain storage logistics, and seamless integration with patient electronic healthcare systems.
"We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test," said chief executive officer James Cheek.
"The NHS has done significant work on both strokes and mini strokes, with campaigns for FAST - face, arms, speech, time - and promoting changing lifestyles to prevent a stroke.
"This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect."
Cheek said clopidogrel was the NICE recommended front-line treatment for those types of strokes.
"However, if you are one of the estimated 20% to 30% who are unable to metabolise Clopidogrel effectively you have the opportunity to be identified quickly and given an alternative medication.
"We are delighted to be part of this change which is in line with our strategy to deliver point-of-care pharmacogenetic testing to positively impact patient outcomes.
"With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve FDA approval and sales being realised from new customers in 2024 we feel there is growing momentum within the group's POC pharmacogenetic testing strategy."
At 1335 BST, shares in Genedrive were up 42.13% at 5.33p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.